TECHNOLOGY LICENSING OPPORTUNITY: NanoFET

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

TRIAD - DOE CONTRACTOR

Contract Value

Not provided

Codes & Classification
Solicitation Number

S-194657

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

AJ12

Additional Details
Set Aside

NONE

Place of Performance

Los Alamos, New Mexico, UNITED STATES

SourceSAM
Documents1
The Department of Energy, through its contractor TRIAD at Los Alamos National Laboratory (LANL), is announcing a technology licensing opportunity for the NanoFiber Engineered Therapeutics Platform (NanoFET). This special notice, classified under NAICS code 541714 (Research and Development in Biotechnology, except Nanobiotechnology), invites pharmaceutical and biodefense organizations to explore licensing arrangements for this innovative therapeutic platform. The opportunity is not a solicitation for external development services, but rather an invitation to commercialize and integrate the NanoFET technology into new or existing product pipelines. NanoFET represents a modular, adaptable scaffold designed to accelerate the development of next-generation immunotherapies. By leveraging self-assembling peptide nanofibers combined with interchangeable nanobody and peptide components, the platform enables rapid creation of targeted treatments that can directly link disease agents to a patient’s immune cells. This architecture is particularly suited to address the limitations of conventional vaccines and biologics, which are often pathogen-specific and slow to adapt to emerging threats. The platform’s modularity allows for the swift exchange of targeting elements, supporting rapid response to new or unknown disease agents—a critical advantage for military, biodefense, and public health applications. Key features of the NanoFET platform include: - A modular design that facilitates rapid adaptation to new disease targets without the need to redesign the core scaffold. - Dual-function constructs capable of bridging disease agents to immune cells, supporting both targeted and broad-spectrum therapeutic responses. - Adjuvant-free immune activation, as the nanofiber structure itself stimulates robust innate immune responses. - Use of small, stable nanobodies that are easier to produce and engineer compared to traditional antibodies, reducing manufacturing complexity and cost. - High-density, multivalent display of antigens or functional components, enhancing immune recognition and therapeutic efficacy. - Compatibility with external biologics, allowing licensees to integrate proprietary or AI-designed targeting molecules onto the nanofiber scaffold. The intended outcomes of this licensing opportunity are to enable commercial partners to develop and deploy advanced immunotherapies across a range of applications, including: - Oncology (e.g., bispecific T-cell engagers, tumor-targeted immunotherapies, combination platforms) - Infectious disease therapeutics (e.g., pan-influenza treatments, broad-spectrum antivirals/antibacterials, emerging pathogen response) - Biodefense and military medicine (e.g., rapid-response countermeasures, field-deployable immune enhancers) - Vaccine development (e.g., multiantigen platforms, adjuvant-free subunit vaccines, mucosal/systemic immunization) - Pharmaceutical biologics and drug delivery (e.g., nanobody-drug conjugates, targeted immune cell delivery) The technology is currently at Technology Readiness Level (TRL) 3, with a U.S. patent pending (reference LA-UR-26-25007). Licensing is available on both exclusive and non-exclusive bases, and LANL’s Technology Partnerships Office is prepared to work with both established and start-up companies to facilitate commercialization. The place of performance and primary point of contact for this opportunity is Los Alamos, New Mexico. Interested parties should direct inquiries to Caleb Ledgerwood or Lindsay Augustyn at [email protected]. Additional information about LANL’s licensing program and available technologies can be found at https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology and m.lanl.gov/tech-search. There are no set-aside requirements or special procurement considerations associated with this notice. The opportunity remains active, with a response deadline of December 18, 2026. Contractors and organizations with expertise in biotechnology, immunotherapy, or related fields are encouraged to evaluate this opportunity for alignment with their strategic objectives and capabilities. For the official notice and further details, please refer to the SAM.gov listing: https://sam.gov/opp/f86920ef287d44e58fb53bcaa9326c29/view.